Mxc-social media, page-290

Hi @pnh88,

That is a common misconception that dementia patients don’t suffer pain or are unaware that they have dementia. Most patients with dementia (not all) are in the aged population and commonly suffer from other co-morbidities (eg degenerative bone & joint diseases, cancer, injuries from falls, post stroke neuropathic pain etc). It can be difficult for staff and carers to determine pain in advanced dementia when the person cannot communicate, below is an example of a modified pain scale used in Australia:

https://apsoc.org.au/PDF/Publications/Abbey_Pain_Scale.pdf

Many patients with early to moderate dementia are aware of their diagnosis & know what medication they are taking for it etc. Of course cognition and lucidity can fluctuate over the course of the day/night & dementia is progressive & terminal.

I can see why a dementia trial may not excite some investors, I think it’s something like a 99% fail rate in clinical trials for Alzheimer’s Disease, however research & trials are now looking beyond the plaque theory in AD.

MXC are looking at Symptom management & quality of life issues for dementia sufferers, rather than cure it seems & will be focusing on behaviour disturbance, pain relief and improvement in specific cognitive function. Even if the first two points are addressed with positive outcomes in trials, that will be a big bonus.

Anyway, a wait on this one, hopefully we get some news on CannEpil soon.